CD274 and non-small cell lung carcinoma: In conclusion, our study revealed that both PFS and OS were similar between MONO and COMBO treatments for patients with NSCLC aged ≥ 70 years with high PD-L1 TPS ≥ 50% but were significantly longer for COMBO than MONO in patients with ECOG PS 0 or non-squamous cell carcinoma.